The launch event of the Precise Dual Antiplatelet Therapy Initiative for Cerebrovascular Diseases, initiated by the China National Clinical Research Center for Neurological Diseases (NCRC-ND),its subsequent awarding ceremony, were successfully held at the First Affiliated Hospital of University of South China on September 23, aimed at further enhancing the diagnosistreatment of neurological diseasespromoting the standardization of treatment among neurologists.

Tan Gang, Vice President of the First Affiliated Hospital of University of South China, delivered a speech at the awarding ceremony. First, he extended a warm welcome to the project teamacademic group members from the NCRC-ND,expressed sincere gratitude to those who have been working on the front lines of medicine. He said that the launchimplementation of the Precise Dual Antiplatelet Therapy Initiative for Cerebrovascular Diseases at the First Affiliated Hospital of University of South China is a major event in the development process of the hospital. Participating in this project will further improve the diagnosistreatment level of neurological diseases in the hospital, promote the standardization of diagnosistreatment among neurologists,facilitate in-depth cooperation with top domestic clinical research teams, which will better protect the health of the people in southern Hunan.

Zhou Lei, Leader of the Transformation Group in the Project Team of NCRC-NDs Precise Dual Antiplatelet Therapy Initiative for Cerebrovascular Diseases, on behalf of NCRC-ND, congratulated the First Affiliated Hospital of University of South China on becoming the first "Application Unit of Precise Dual Antiplatelet Therapy Initiative for Cerebrovascular Diseases" of NCRC-ND in Hengyang.

Scene of the awarding ceremony

At the conference, the awarding ceremony of the Application Unit of Precise Dual Antiplatelet Therapy for Cerebrovascular Diseases of NCRC-ND was held, marking that the First Affiliated Hospital of University of South China officially became the precision dual antiplatelet therapy application unit for cerebrovascular diseases of NCRC-ND. Subsequently, the Academic Manager of the Project Management Department of NCRC-ND gave a detailed introduction to the background, clinical application,project progress of the Precise Dual Antiplatelet Therapy Initiative for Cerebrovascular Diseases. Approximately 3 million new high-risk, non-disabling ischemic cerebrovascular disease patients are diagnosed annually nationwide, with approximately 57% of patients carrying the CYP2C19 loss-of-function gene. This group of patients has a poor therapeutic effecta high recurrence rate with the current guideline-recommended treatment plan of clopidogrel combined with aspirin from the CHANCE study. The major achievements of the CHANCE-2 study, a major scientific research project undertaken by NCRC-ND during Chinas 13th Five-Year Plan period, were published in the New England Journal of Medicine (NEJM) on October 28, 2021. According to the research findings of CHANCE-2, 30,000 recurrent stroke cases could be prevented annually nationwide. At a direct hospitalization cost of RMB 35,000 per patient, approximately RMB 1 billion in medical expenses can be saved each year.

NCRC-ND is the sole national clinical research center for neurological diseases in Chinais currently the largest clinical medical research platform in the field of neurological diseases in China. It possesses the worlds largest international-standardized clinicalsample resource library for neurological diseases,is one of the three major neurosurgery research centers in the world. The Precise Dual Antiplatelet Therapy Initiative for Cerebrovascular Diseases is a major scientific research project undertaken by NCRC-ND during Chinas 13th Five-Year Plan period, marking the entry of stroke treatmentthe era of precise dual antiplatelet therapy. Next, the First Affiliated Hospital of University of South China will continue to improve its comprehensive treatment capabilities in stroke prevention, treatment, rehabilitation, etc.,promote the construction of the DiagnosisTreatment Center for Neurological Diseases to a new level, reinforcing health security for the public.